Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function.
hypertension
lisinopril
paediatrics
population pharmacokinetics
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
revised:
06
10
2023
received:
16
06
2023
accepted:
11
10
2023
pubmed:
21
10
2023
medline:
21
10
2023
entrez:
20
10
2023
Statut:
aheadofprint
Résumé
Lisinopril, an angiotensin-converting enzyme inhibitor, is a frequently prescribed antihypertensive drug in the paediatric population, while being used off-label under the age of 6 years in the USA and for all paediatric patients globally. The SAFEPEDRUG project (IWT-130033) investigated lisinopril pharmacokinetics in hypertensive paediatric patients corresponding with the day-to-day clinical population. The dose-escalation pilot study included 13 children with primary and secondary hypertension who received oral lisinopril once daily in the morning; doses ranged from 0.05 to 0.2 mg kg A 1-compartment model with first-order absorption and first-order elimination optimally describes the data. Parameter estimates of absorption rate constant (0.075 h Lisinopril dose and regimen adjustments for paediatric patients should include eGFR on top of weight adjustments. An expanded model characterizing the pharmacodynamic effect is required to identify the optimal dose and dosing regimen.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agency for Innovation by Science and Technology in Flanders (IWT)
ID : IWT/SBO 130033
Informations de copyright
© 2023 British Pharmacological Society.
Références
Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795-800. doi:10.1016/S0895-7061(03)00900-2
Raes A, Malfait F, Van Aken S, France A, Donckerwolcke R, Vande Walle J. Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. J Renin Angiotensin Aldosterone Syst. 2007;8(1):3-12. doi:10.3317/JRAAS.2007.004
Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011;33(10):1331-1356. doi:10.1016/J.CLINTHERA.2011.09.003
Wühl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66(2):768-776. doi:10.1111/j.1523-1755.2004.00802.x
Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 Pt 1):475-482. doi:10.1542/PEDS.113.3.475
Lande MB, Batisky DL, Kupferman JC, et al. Neurocognitive function in children with primary hypertension. J Pediatr. 2017;180:148-155.e1. doi:10.1016/j.jpeds.2016.08.076
Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation. 2013;128(3):217-224. doi:10.1161/CIRCULATIONAHA.113.001614
Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics. 2003;111(1):61-66. doi:10.1542/PEDS.111.1.61
Daniels SR, Loggie JMH, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97(19):1907-1911. doi:10.1161/01.CIR.97.19.1907
Yang L, Magnussen CG, Yang L, Bovet P, Xi B. Elevated blood pressure in childhood or adolescence and cardiovascular outcomes in adulthood: a systematic review. Hypertension. 2020;75(4):948-955. doi:10.1161/HYPERTENSIONAHA.119.14168
Siddiqi N, Shatat IF. Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol. 2020;35(11):2049-2065. doi:10.1007/s00467-019-04314-7
Feickert M, Burdman I, Makowski N, Ali M, Bartel A, Burckhardt BB. A continued method performance monitoring approach for the determination of pediatric renin samples-application within a European clinical trial. Clin Chem Lab Med. 2020;58(11):1847-1855. doi:10.1515/CCLM-2019-1162
Snauwaert E, Vande Walle J, De Bruyne P. Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. Arch Dis Child. 2017;102(1):63-71. doi:10.1136/archdischild-2016-310582
Trachtman H, Frymoyer A, Lewandowski A, et al. Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: implications for starting dose selection. Clin Pharmacol Ther. 2015;98(1):25-33. doi:10.1002/cpt.127
Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007;22(5):695-701. doi:10.1007/s00467-006-0399-5
Wimmer S, Rascher W, McCarthy S, Neubert A. The EU Paediatric Regulation: still a large discrepancy between therapeutic needs and approved Paediatric investigation plans. Pediatr Drugs. 2014;16(5):397-406. doi:10.1007/S40272-014-0082-4
Balat A. Children with chronic kidney disease and hypertension: could hypertension footprints be early biomarkers? Curr Hypertens Rev. 2014;10(2):86-98. doi:10.2174/1573402111666141231150433
Wühl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650. doi:10.1056/NEJMoa0902066
Beermann B. Pharmacokinetics of lisinopril. Am J Med. 1988;85(3B):25-30. doi:10.1016/0002-9343(88)90346-4
Gomez HJ, Cirillo VJ, Moncloa F. The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol. 1987;9(Suppl 3):S27-S34. doi:10.1097/00005344-198700003-00008
Lui PCW, Fan YS, Xu G, et al. Apoptotic and necrotic effects of tumour necrosis factor-alpha potentiated with hyperthermia on L929 and tumour necrosis factor-alpha-resistant L929. Int J Hyperthermia. 2010;26(6):556-564. doi:10.3109/02656736.2010.486777
Chase SL, Sutton JD. Lisinopril: a new angiotensin-converting enzyme inhibitor. Pharmacotherapy. 1989;9(3):120-128. doi:10.1002/J.1875-9114.1989.TB04117.X
Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with. Hypertension. 1989;27(1):57-65. doi:10.1111/j.1365-2125.1989.tb05335.x
Germovsek E, Barker CIS, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol. 2017;83(4):777-790. doi:10.1111/BCP.13160
Hill KD, Li JS. Childhood hypertension: an underappreciated epidemic? Pediatrics. 2016;138(6):e20162857. doi:10.1542/PEDS.2016-2857
Tamimi JJI, Salem II, Alam SM, Zaman Q, Dham R. Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. Biopharm Drug Dispos. 2005;26(8):335-339. doi:10.1002/BDD.465
Rashid M, Sarfraz M, Arafat M, et al. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. BMC Pharmacol Toxicol. 2020;21(1):56. doi:10.1186/s40360-020-00429-y
Xie F, Van Bocxlaer J, Vermeulen A. Physiologically based pharmacokinetic modelling of lisinopril in children: a case story of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2021;87(3):1203-1214. doi:10.1111/BCP.14492
Anderson BJ, Holford NHG. Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 2011;21(3):222-237. doi:10.1111/j.1460-9592.2011.03536.x
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(Supplement_2):555-576. doi:10.1542/PEDS.114.S2.555
Sorof JM, Portman RJ. White coat hypertension in children with elevated casual blood pressure. J Pediatr. 2000;137(4):493-497. doi:10.1067/MPD.2000.108394
Vidi SR. Role of hypertension in progression of chronic kidney disease in children. Curr Opin Pediatr. 2018;30(2):247-251. doi:10.1097/MOP.0000000000000595
Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637. doi:10.1681/ASN.2008030287
Schmidt RL, Straseski JA, Raphael KL, Adams AH, Lehman CM. A risk assessment of the Jaffe vs enzymatic method for creatinine measurement in an outpatient population. PLoS ONE. 2015;10(11):e0143205. doi:10.1371/JOURNAL.PONE.0143205
FDA. CVM GFI #208 (VICH GL49) Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: validation of analytical methods used in residue depletion studies. Accessed February 28, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-208-vich-gl49-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food
Publications Office of the EU. 2002/657/EC: Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (Text with EEA relevance) (notified under document number C(2002) 3044). Accessed February 28, 2023. https://op.europa.eu/en/publication-detail/-/publication/ed928116-a955-4a84-b10a-cf7a82bad858/language-en
European Medicines Agency. 2** Committee for Medicinal Products for Human Use (CHMP) Guideline on bioanalytical method validation. 1922. Accessed February 28, 2023. www.ema.europa.eu/contact
Knecht J, Stork G. Prozentuales und logarithmisches Verfahren zur Berechnung von Eichkurven. Fresenius Z. Anal. Chem. 1974;270(2):97-99. doi:10.1007/BF00434058/METRICS
Veterinary Drug Residues. Directorate General for Agriculture EC Brussels published on behalf of Commission of the European Communities.
Anderson BJ, Allegaert K, Holford NHG. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006;165(11):741-746. doi:10.1007/S00431-006-0188-Y
European Medicines Agency. ICH E11(R1) Guideline on clinical investigation of medicinal products in the pediatric population (EMA/CPMP/ICH/2711/1999 rev. 1.). 2017. 1-12. https://www.ema.europa.eu/documents/scientific-guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1_en.pdf
Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941-2952. doi:10.1002/JPS.23574
Holford NHG, Anderson BJ. Why standards are useful for predicting doses. Br J Clin Pharmacol. 2017;83(4):685-687. doi:10.1111/BCP.13230
Knütter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008;327(2):432-441. doi:10.1124/jpet.108.143339
Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2000;2(1):22-28. doi:10.1208/PS020103
Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol. 1988;2(3):239-256. doi:10.1111/J.1472-8206.1988.TB00635.X
Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95(4):112-117. doi:10.1136/ADC.2009.163055
Misaka S, Ono Y, Uchida A, et al. Impact of green tea catechin ingestion on the pharmacokinetics of lisinopril in healthy volunteers. Clin Transl Sci. 2021;14(2):476-480. doi:10.1111/CTS.12905
Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y. Physiologically based pharmacokinetic models are effective support for pediatric drug development. AAPS PharmSciTech. 2021;22(6):208. doi:10.1208/S12249-021-02076-W
Hermida RC, Ayala DE, Smolensky MH, Fernández JR, Mojón A, Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39(5):277-292. doi:10.1038/HR.2015.142